You are here

VISDEX CORP

Company Information
Address
1751 CAPISTRANO AVE
BERKELEY, CA 94707-1805
United States



Information

UEI: N/A

# of Employees: 2


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Phase Contrast OCT for Non-Invasive Imaging of Retinovascular Disease

    Amount: $800,526.00

    DESCRIPTION (provided by applicant): Since its introduction in the 1960's, fluorescein angiography (FA) has been the gold standard for retinal vascular diagnosis. However, FA is costly, invasive, ...

    STTRPhase II2013Department of Health and Human Services National Institutes of Health
  2. Characterization of Exudative Macular Degeneration and Diabetic Retinopathy Using

    Amount: $153,908.00

    DESCRIPTION (provided by applicant): Since its first use in the retina in 1961, fluorescein angiography (FA) has been the gold standard for objective characterization of retinovascular disease (e.g. d ...

    STTRPhase I2010Department of Health and Human Services National Institutes of Health
  3. Novel Treatment for Post-LASIK Ectasia

    Amount: $347,984.00

    DESCRIPTION (provided by applicant): Of the 1.4 million refractive surgeries performed each year using laser assisted in situ keratomileusis (LASIK) in the U.S., 1 in 2500 will result in post-LASIK ec ...

    STTRPhase I2009Department of Health and Human Services National Institutes of Health
  4. Novel Treatment for Degenerative Myopia

    Amount: $645,867.00

    DESCRIPTION (provided by applicant): Myopia affects 30% of the population in the U.S. and Europe, and 70-90% of the population in some Asian countries. High myopia of greater than 8 diopters affects ...

    STTRPhase II2008Department of Health and Human Services National Institutes of Health
  5. Novel Treatment for Degenerative Myopia

    Amount: $270,496.00

    DESCRIPTION (provided by applicant): Photopolymerization has provided a powerful tool for tissue engineering through localized synthesis of therapeutic materials in situ. To date, strategies to create ...

    STTRPhase I2006Department of Health and Human Services National Institutes of Health
  6. Novel Treatment for Degenerative Myopia

    Amount: $270,496.00

    DESCRIPTION (provided by applicant): Photopolymerization has provided a powerful tool for tissue engineering through localized synthesis of therapeutic materials in situ. To date, strategies to create ...

    SBIRPhase I2006Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government